Rare diseases do not discriminate; they affect people from all walks of life and in all economic circumstances. Sanofi’s responsibility to the patient community extends beyond the research and development of effective therapies to include providing support to patients, who often have nowhere else to go–no matter who they are or where they live.
Sanofi Genzyme has two Humanitarian Programs, which provide support to patients with five different lysosomal storage disorders (LSDs), a group of rare genetic conditions caused by enzyme deficiencies, as well as patients with hemophilia, a rare genetic disorder in which a person’s blood does not clot normally.
Throughout this month, we’ll be sharing stories of patients around the world who receive this support and who inspire Sanofi’s employees around the world.
Sanofi Genzyme’s vision is to help transform the way hemophilia care is delivered in the developing world, where the vast majority of people with hemophilia have limited or no access to diagnosis and treatment.
That’s why, in June 2020, Sanofi, together with our partner Sobi, committed to donate up to 500 million additional IUs of clotting factor to the World Federation of Hemophilia (WFH) Humanitarian Aid Program, fulfilling the 2014 pledge to donate up to 1 billion IUs for humanitarian use. This unparalleled donation helps to address the treatment gap and raise standard of care for people living with hemophilia in the developing world.
Since shipments began in 2015, our commitment has helped to treat over 160,000 acute bleeds, enabling more than 2,300 surgeries-including life and limb-saving operations-and helping to increase the percentage of children receiving treatment from 14 to 37 percent.
These donations have been life changing for patients and their families. Here are two of their stories: